Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ABBV logo ABBV
Upturn stock ratingUpturn stock rating
ABBV logo

AbbVie Inc (ABBV)

Upturn stock ratingUpturn stock rating
$176.9
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/27/2025: ABBV (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit 6.7%
Avg. Invested days 50
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/27/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 313.20B USD
Price to earnings Ratio 74.08
1Y Target Price 210.01
Price to earnings Ratio 74.08
1Y Target Price 210.01
Volume (30-day avg) 6202936
Beta 0.54
52 Weeks Range 148.19 - 216.66
Updated Date 04/24/2025
52 Weeks Range 148.19 - 216.66
Updated Date 04/24/2025
Dividends yield (FY) 3.71%
Basic EPS (TTM) 2.39

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-04-25
When Before Market
Estimate -
Actual -

Profitability

Profit Margin 7.59%
Operating Margin (TTM) 36.66%

Management Effectiveness

Return on Assets (TTM) 8.49%
Return on Equity (TTM) 62.29%

Valuation

Trailing PE 74.08
Forward PE 14.29
Enterprise Value 369002045150
Price to Sales(TTM) 5.56
Enterprise Value 369002045150
Price to Sales(TTM) 5.56
Enterprise Value to Revenue 6.55
Enterprise Value to EBITDA 24.75
Shares Outstanding 1768979968
Shares Floating 1761471078
Shares Outstanding 1768979968
Shares Floating 1761471078
Percent Insiders 0.1
Percent Institutions 73.81

Analyst Ratings

Rating 4
Target Price 210.93
Buy 4
Strong Buy 11
Buy 4
Strong Buy 11
Hold 11
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

AbbVie Inc

stock logo

Company Overview

overview logo History and Background

AbbVie Inc. was founded in 2013 when it separated from Abbott Laboratories. It has grown through internal research and development and strategic acquisitions, focusing on developing and marketing innovative pharmaceuticals.

business area logo Core Business Areas

  • Immunology: Focuses on treatments for autoimmune diseases like rheumatoid arthritis and Crohn's disease. Key product: Humira (biosimilars now affecting sales), Skyrizi, Rinvoq.
  • Oncology: Develops therapies for various cancers, including hematological malignancies and solid tumors. Key products: Imbruvica, Venclexta.
  • Neuroscience: Focuses on treatments for neurological and psychiatric disorders. Key products: Botox Therapeutic, Ubrelvy.
  • Aesthetics: Offers a range of aesthetic products including Botox Cosmetic, Juvederm dermal fillers. Competitors include Galderma and Merz Pharma.

leadership logo Leadership and Structure

AbbVie is led by CEO Richard A. Gonzalez. The organizational structure is divided into research and development, commercial operations, and support functions.

Top Products and Market Share

overview logo Key Offerings

  • Humira: A biologic drug used to treat autoimmune diseases. Once a blockbuster, its revenue has declined due to biosimilar competition. Revenue peaked around $20 billion annually. Competitors: Biosimilars from Amgen (AMGN), Novartis (NVS), and others; alternative treatments from J&J (JNJ), Eli Lilly (LLY), and others.
  • Skyrizi: A biologic used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. Growing rapidly. Aiming to offset Humira revenue loss. Competitors: J&J's Stelara, Novartis' Cosentyx, Eli Lilly's Taltz.
  • Rinvoq: An oral JAK inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. Also a key growth driver. Competitors: Pfizer's Xeljanz, Eli Lilly's Olumiant.
  • Imbruvica: A cancer drug used to treat blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia. Competitors: AstraZeneca's Calquence, BeiGene's Brukinsa.
  • Botox Cosmetic/Therapeutic: Botulinum toxin used for cosmetic and therapeutic purposes. Competitors: Galderma's Dysport, Merz Pharma's Xeomin.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulations, and patent protection. Trends include personalized medicine, gene therapy, and digital health.

Positioning

AbbVie is a major player in the pharmaceutical industry, known for its strong presence in immunology, oncology, and neuroscience. Its competitive advantage lies in its innovative pipeline and global commercial infrastructure.

Total Addressable Market (TAM)

The global pharmaceutical market is estimated to be worth over $1 trillion. AbbVie is positioned to capture a significant portion of this market through its diversified portfolio and pipeline, potentially addressing $200-$300 billion across its therapeutic areas.

Upturn SWOT Analysis

Strengths

  • Strong product portfolio
  • Robust R&D pipeline
  • Global commercial presence
  • High profit margins
  • Experienced management team

Weaknesses

  • Reliance on Humira (decreasing)
  • Patent expiration risk
  • High debt levels (from acquisitions)
  • Exposure to biosimilar competition
  • Pricing pressure

Opportunities

  • Expansion into new therapeutic areas
  • Strategic acquisitions
  • Growth in emerging markets
  • Development of innovative therapies
  • Partnerships and collaborations

Threats

  • Increasing competition
  • Regulatory changes
  • Economic downturns
  • Patent challenges
  • Biosimilar erosion

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • PFE
  • MRK
  • BMY
  • LLY
  • NVS

Competitive Landscape

AbbVie faces intense competition from other major pharmaceutical companies. AbbVie has a strong presence in immunology and oncology, while competitors have strengths in other areas.

Major Acquisitions

Allergan

  • Year: 2020
  • Acquisition Price (USD millions): 63000
  • Strategic Rationale: Acquisition of Allergan diversified AbbVie's product portfolio and reduced reliance on Humira. It added aesthetics (Botox), women's health, and other therapeutic areas.

Growth Trajectory and Initiatives

Historical Growth: AbbVie's growth has been driven by Humira and other key products. Growth has slowed with biosimilar competition.

Future Projections: Analyst estimates vary, but generally project continued growth driven by Skyrizi, Rinvoq, and other pipeline products.

Recent Initiatives: Recent strategic initiatives include acquisitions (e.g., Allergan) and investments in R&D to expand the product portfolio.

Summary

AbbVie is a major pharmaceutical company with a strong presence in immunology, oncology, and neuroscience. Its growth has been historically driven by Humira, but it is now diversifying its portfolio to offset biosimilar competition. Strategic acquisitions like Allergan have expanded its reach, but high debt levels remain a concern. AbbVie's continued success depends on its ability to innovate and bring new products to market.

Similar Companies

BMYratingrating

Bristol-Myers Squibb Company

$49.82
Large-Cap Stock
0%
PASS

BMYratingrating

Bristol-Myers Squibb Company

$49.82
Large-Cap Stock
0%
PASS

JNJratingrating

Johnson & Johnson

$157.75
Large-Cap Stock
0%
PASS

JNJratingrating

Johnson & Johnson

$157.75
Large-Cap Stock
0%
PASS

LLYratingrating

Eli Lilly and Company

$827.54
Large-Cap Stock
0%
PASS

LLYratingrating

Eli Lilly and Company

$827.54
Large-Cap Stock
0%
PASS

MRKratingrating

Merck & Company Inc

$77.85
Large-Cap Stock
0%
PASS

MRKratingrating

Merck & Company Inc

$77.85
Large-Cap Stock
0%
PASS

NVSratingrating

Novartis AG ADR

$111.41
Large-Cap Stock
0%
PASS

NVSratingrating

Novartis AG ADR

$111.41
Large-Cap Stock
0%
PASS

PFEratingrating

Pfizer Inc

$22.53
Large-Cap Stock
0%
PASS

PFEratingrating

Pfizer Inc

$22.53
Large-Cap Stock
0%
PASS

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Investor Relations
  • Analyst Reports
  • Industry Publications

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change. Consult with a financial professional before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About AbbVie Inc

Exchange NYSE
Headquaters North Chicago, IL, United States
IPO Launch date 2013-01-02
CEO & Director Mr. Robert A. Michael CPA
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 55000
Full time employees 55000

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​